ESLA (Estrella Immunopharma) Debt-to-Equity : 0.00 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Debt-to-Equity?

Estrella Immunopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. Estrella Immunopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. Estrella Immunopharma's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $4.27 Mil. Estrella Immunopharma's debt to equity for the quarter that ended in Jun. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Estrella Immunopharma's Debt-to-Equity or its related term are showing as below:

ESLA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: 0.07

ESLA's Debt-to-Equity is ranked better than
64.69% of 1031 companies
in the Biotechnology industry
Industry Median: 0.14 vs ESLA: 0.07

Estrella Immunopharma Debt-to-Equity Historical Data

The historical data trend for Estrella Immunopharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Debt-to-Equity Chart

Estrella Immunopharma Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Debt-to-Equity

N/A

Estrella Immunopharma Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Equity	Get a 7-Day Free Trial							-	0.03	-	-	-

Competitive Comparison of Estrella Immunopharma's Debt-to-Equity

For the Biotechnology subindustry, Estrella Immunopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Estrella Immunopharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's Debt-to-Equity falls into.

Estrella Immunopharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Estrella Immunopharma's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	4.273
	=	0.00

Estrella Immunopharma's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	4.273
	=	0.00

Estrella Immunopharma (NAS:ESLA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Estrella Immunopharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608

Website

https://www.estrellabio.com

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma Headlines

From GuruFocus

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

By Business Wire • 08-14-2024